Please use this identifier to cite or link to this item:
Title: Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Austin Authors: Jerums, George ;Panagiotopoulos, Sianna ;Forbes, Josephine M;Osicka, Tanya M;Cooper, Mark E
Affiliation: Endocrine Unit, Austin Health, University of Melbourne, Studley Road, 3084 Heidelberg, Australia
Issue Date: 1-Nov-2003
Publication information: Archives of Biochemistry and Biophysics; 419(1): 55-62
Abstract: Advanced glycation endproducts (AGEs) have been postulated to play a role in the development of both nephropathy and large vessel disease in diabetes. However, it is still not clear which AGE subtypes play a pathogenetic role and which of several AGE receptors mediate AGE effects on cells. This review summarises the renoprotective effect of inhibitors of AGE formation, including aminoguanidine, and of cross-link breakers, including ALT-711, on experimental diabetic nephropathy and on mesenteric vascular hypertrophy. It also demonstrates similar effects of aminoguanidine and ramipril (an angiotensin converting enzyme inhibitor) on fluorescent and immunoassayable AGE levels, renal protein kinase C activity, nitrotyrosine expression, lysosomal function, and protein handling in experimental diabetes. These findings indicate that inhibition of the renin angiotensin system blocks both upstream and downstream pathways leading to tissue injury. We postulate that the chemical pathways leading to advanced glycation endproduct formation and the renin angiotensin systems may interact through the generation of free radicals, induced both by glucose and angiotensin II. There is also evidence to suggest that AGE-dependent pathways may play a role in the development of tubulointerstitial fibrosis in the diabetic kidney. This effect is mediated through RAGE and is TGF-beta and CTGF-dependent.
Gov't Doc #: 14568009
ORCID: 0000-0002-0845-0001
Journal: Archives of biochemistry and biophysics
Type: Journal Article
Subjects: Albuminuria.drug therapy
Angiotensin-Converting Enzyme Inhibitors.pharmacology
Diabetes Mellitus, Type 2.physiopathology
Diabetic Angiopathies.metabolism
Diabetic Nephropathies.metabolism
Enzyme Inhibitors.pharmacology
Glycosylation End Products, Advanced.metabolism
Protein Kinase C.drug effects
Renin-Angiotensin System.drug effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.